Revance Therapeu Stock Price, News & Analysis

Revance Therapeutics, Inc. (NASDAQ: RVNC), referred to as Revance, is described as a biotechnology company focused on aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. According to company and transaction communications, Revance operates in the pharmaceutical preparation manufacturing space within the broader manufacturing sector, with a portfolio centered on neuromodulator and dermal filler products used in aesthetic medicine and select therapeutic indications.

Revance has been the subject of a cash acquisition by Crown Laboratories, Inc. ("Crown"), a privately held global skincare company. Crown announced the commencement of a friendly tender offer to acquire all outstanding common shares of Revance under an Amended and Restated Merger Agreement, followed by an increase in the offer price and subsequent extensions of the tender offer. Crown and Revance later announced the expiration of the tender offer and the satisfaction of its conditions, and Crown reported the completion of the acquisition through a second-step merger. Following this transaction, Revance’s common stock is expected to be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended. As a result, RVNC primarily represents the historical public equity of Revance prior to its acquisition by Crown.

Business focus and product portfolio

In transaction-related disclosures, Revance is described as a biotechnology company "setting the new standard in healthcare" with aesthetic and therapeutic offerings. Its portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers. The RHA technology is proprietary to and manufactured in Switzerland by Teoxane SA. Revance has partnered with Teoxane SA to supply hyaluronic acid (HA) fillers for U.S. distribution, and it is identified as an independent distributor of the RHA Collection for the U.S. market.

Revance has also disclosed partnerships with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and with Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China. These relationships indicate that Revance’s activities span product development, manufacturing collaborations and commercial distribution arrangements in aesthetic injectables and related therapeutic uses.

Corporate structure and ownership changes

Multiple press releases outline a sequence of events in which Crown launched and then improved a cash tender offer for all outstanding shares of Revance, with the Revance Board of Directors unanimously recommending that stockholders tender their shares. The offer price was increased to $3.65 per share in cash, and the tender offer was extended to allow additional time for stockholders to participate. Crown and Revance later announced that a substantial majority of Revance shares had been validly tendered, satisfying the conditions to close the transaction.

Following the expiration of the tender offer and acceptance of tendered shares, Crown completed the acquisition of Revance via a second-step merger. Crown reported that, after this merger, Revance’s common stock would be delisted from the NASDAQ Global Select Market and deregistered. This means that, while Revance continues to operate as a biotechnology business within Crown’s broader skincare and aesthetics platform, RVNC as a standalone publicly traded ticker is transitioning into a historical reference for the former public company.

Headquarters and geographic context

In transaction communications, Revance states that its global headquarters and experience center are located in Nashville, Tennessee. The company also references international elements of its operations through partnerships, including Teoxane SA in Switzerland and Shanghai Fosun Pharmaceutical in China, in connection with the RHA Collection and DAXXIFY commercialization. These references highlight that, while headquartered in the United States, Revance’s business model involves cross-border collaborations and distribution arrangements.

Relationship with Crown Laboratories

Crown describes itself as a privately held, fully integrated global skincare company focused on aesthetic, premium and therapeutic skincare products. Crown has emphasized that acquiring Revance strengthens its position in the aesthetics and skincare industry and supports a portfolio organized around facial aesthetics. From the perspective of RVNC stock, this acquisition marks the transition of Revance from an independent, publicly traded biotechnology issuer to a Crown-owned business that is no longer expected to trade on NASDAQ once the delisting and deregistration steps are completed.

For investors researching RVNC, it is important to distinguish between Revance’s ongoing operating activities as a Crown subsidiary and the status of RVNC as a public equity security. The tender offer and subsequent merger mean that former public shareholders receive cash consideration, and the ticker’s role shifts to documenting the historical record of Revance as a public company.

Historical development focus

Earlier descriptions of Revance characterize it as a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. Those descriptions also reference proprietary botulinum toxin compounds and a patented peptide delivery system intended to address unmet needs in the neurotoxin market. While these legacy descriptions provide context on Revance’s historical research and development focus, more recent transaction-related disclosures emphasize the commercial portfolio of DAXXIFY and the RHA Collection, along with strategic partnerships for biosimilar development and international commercialization.

RVNC as a historical ticker

Given the completion of Crown’s acquisition and the planned delisting and deregistration of Revance’s common stock, RVNC should be viewed primarily as a historical ticker symbol for Revance Therapeutics, Inc. Investors and researchers using RVNC-related pages can expect to find information that reflects Revance’s business profile as a biotechnology company in aesthetic and therapeutic injectables, its key product portfolio and partnerships, and the details of its acquisition by Crown. For current operational information, Crown’s communications and any post-acquisition disclosures provide the most direct view of how Revance’s assets and capabilities are integrated within Crown’s broader skincare and aesthetics platform.